UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934

For the Month of July 2014

001-36203 (Commission File Number)

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951778, Israel (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☑ Form 40-F □

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

On July 7, 2014, Can-Fite BioPharma Ltd. (the "Company") made available an updated investor presentation on its website. A copy of the investor presentation is attached hereto as Exhibit 99.1 and may be viewed in the Investor Information section of the Company's website at <u>www.canfite.com</u>.

In addition, the 2014 Annual Meeting of Shareholders (the "Annual Meeting") was convened on Monday, July 7, 2014, however, it was adjourned for one week to the same day, time and place due to lack of quorum. Accordingly, the Company's Annual Meeting will be reconvened on Monday, July 14, 2014 at 10:00am, Israel time at the Company's offices located at 10 Bareket Street, Petach Tikva, Israel.

Exhibit Index

Exhibit No.	Description
99.1	Company Presentation, dated July 2014


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Can-Fite BioPharma Ltd.

By: <u>/s/ Motti Farbstein</u> Motti Farbstein Chief Operating and Financial Officer

Date July 8, 2014



Small Molecules For Big Clinical Needs™

(NYSE MKT:CANF) (TASE:CFBI)

Forward Looking Statement


4

This presentation contains forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission (the "SEC"), press releases or oral statements made by or with the approval of one of Can-Fite's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in Can-Fite's filings with the SEC and in its periodic filings with the Tel-Aviv Stock Exchange.

(NYSE MKT:CANF) (TASE:CFBI)



From Concept to Technology



Platform Technology

Therapeutic Target

- A3 adenosine receptor (A3AR)
- · Highly expressed in inflammatory cells

Drug product

۲

- Small molecules
- Orally bioavailable drugs
- A3AR ligands

Pharmacology profile

Anti-inflammatory and anti-cancer effects

Therapeutic index


 High safety profile and proven efficacy in Phase II clinical studies


A3AR is a Biological Predictive Marker

Used to predict patient's response to the drug

Targeted therapy, specifically aimed at diseased cells

(NYSE MKT:CANF) (TASE:CFBI)





(IIIIII) As Adenosine Receptor (AsAR)



Company Profile

Can-Fite BioPharma

Advanced clinical stage drug development company


Platform technology


Small molecule ligands targeting the A3 adenosine receptor to treat:

- Autoimmune Inflammatory diseases
- Cancer
- Ophthalmic diseases

Two regional out-licensing deals

- Japan: for inflammation (including rheumatoid arthritis and psoriasis)
- Korea: for rheumatoid arthritis
- Sizable up front and milestone payments and royalties (significant portion received already)





(MIMI) A3 Adenosine Receptor (A3AR)

(NYSE MKT:CANF) (TASE:CFBI)



Equity Profile

Ticker on NYSE: CANF

Ticker on Israeli TASE: CFBI

Price of ADR: \$3.75 (1 ADR = 2 Ordinary Shares)

52 Week Range: \$3.30 - \$9.46

Shares Out: 17.7M Ordinary Shares

Market Capitalization: ~\$33M


Avg. Trading Volume (30 day): 25,437 ADRs

As of July 6, 2014

(NYSE MKT:CANF) (TASE:CFBI)



Market Opportunity*



Drug Development Pipeline



Corporate Partnership

Regional out-licensing deals

- SEIKAGAKU CORPORATION [Traded on the Tokyo Stock Exchange (Ticker:4548)]
- Exclusive license to develop and commercialize CF101 in Japan
- Up to \$20 M in upfront, milestone and annual payments (\$7.5M received to date)
- Up to 12% royalties

(Traded on South Korean Stock Exchange (Ticker: A009290)]

- Exclusive regional license to develop and commercialize CF101 for the treatment of rheumatoid arthritis in Korea
- \$1.5 M in upfront and milestone payments (\$0.5M received to date)
- 7% royalties. Such payments are subject to development and marketing milestones

Scientific Collaborations

Collaborations with two leading medicinal chemistry laboratories in the field of A₃AR for supply of new molecules

- U.S. National Institutes of Health (NIH)
- Leiden University, the Netherlands

(NYSE MKT:CANF) (TASE:CFBI)





CF101 Drug Profile

Properties

۲

- Highly Selective A3AR Agonist
- Nucleoside derivative
- Molecular weight 510.29
- Water insoluble
- Orally bioavailable
- Half life time in blood 8-9 hours
- Is not metabolized in the body (secreted unchanged)

Fishmanet al. Drug Discovery Today 17:359-366. 2011.

(NYSE MKT:CANF) (TASE:CFBI)


Anti-Inflammatory Effect

Proof of concept in pre-clinical pharmacology studies:

- Rheumatoid Arthritis
- Osteoarthritis
- Inflammatory Bowel Disease
- Uveitis

10

Mechanism of Action



BioPharma Ltd.

CF101 – Phase II Rheumatoid Arthritis Study

Study Rationale - Phase IIa Data

۲

 Strong correlation found between A3AR expression in PBMNCs (a class of circulating white blood cells) at baseline and response of patients to CF101 drug treatment

Phase II - Study Protocol


- Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled
- CF101 Administered Orally as Monotherapy for 12 Weeks
- Patients with Active Rheumatoid Arthritis
- Elevated Baseline Expression Levels of A₃ Adenosine Receptor

Study Primary End Points

- ACR20 response
- Safety parameters

(NYSE MKT:CANF) (TASE:CFBI)

Phase IIa Data








RA Phase II – Efficacy

۲


70% of patients had an over-expression of the Biomarker (>1.5 units) and were eligible to be enrolled to the study



RA Phase II – Efficacy in Naive Patients

۲

Patients with No Prior Systemic Therapy



CF101 - Psoriasis

۲

Phase II/III - Study Protocol

- Double-blind, placebo-controlled study to test efficacy of CF101 in 300 patients with moderate-to-severe plaque psoriasis
- 3 arms: 1 mg, 2 mg and of CF101 and placebo
 - All patients receiving placebo were switched to either
 - 1 mg or 2 mg CF101 after 12 weeks
- Study duration 24 weeks
- Interim analysis after 100 patients

Primary End Point

- PASI 75 and PGA after 12 weeks
- Safety parameters

(NYSE MKT:CANF) (TASE:CFBI)

 Before
 After

 date
 Image: Study Scheme

 ks
 Study Scheme

 Image: Study Scheme
 Image: Study Scheme


14

0

12



Psoriasis - Interim Analysis Data



CF102 for the Treatment of Liver Cancer

Properties

۲


- Highly Selective A3AR Agonist
- · Nucleoside derivative
- Molecular weight 544.73
- Water insoluble
- Orally bioavailable
- Half life time in blood 12 hours

Anti-Cancer Effect

Proof of concept in pre-clinical pharmacology studies:

- Hepatocellular Carcinoma
- Colon Carcinoma
- Prostate Cancer
- Melanoma

Mechanism of Action



(NYSE MKT:CANF) (TASE:CFBI)



CF102 for the Treatment of Liver Cancer

Phase I/II Proof of Concept Study

Study Synopsis

Phase I/II, open-label, dose-escalation study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered CF102 in patients with advanced primary liver cancer

Results

- Very favorable safety profile and lack of hepatotoxicity
- Prolongation of survival time
- Regression of skin tumor metastases
- Stable disease (22%)
- Proof of concept for A3AR utilization as a biomarker
- U.S. FDA Orphan Drug Approval (Feb 2012)



Stemmer et al. The Oncologist, 2012

Current Status

Initiation of Phase II study - Second-Line Treatment of Advanced Hepatocellular Carcinoma in Subjects with Child-Pugh B 78 patients; US, Europe and Israel

(NYSE MKT:CANF) (TASE:CFBI)



Intellectual Property Portfolio

- ✓ Exclusive licensee of the U.S. National Institutes of Health (NIH) and Leiden University in the Netherlands for patents covering A₃AR Agonists
- ✓ 15 patent families

۲

- 150 patents issued and pending patents applications internationally
- IP covers composition of matter, synthesis of matter, and clinical applications

(NYSE MKT:CANF) (TASE:CFBI)



Spotlight on 2014 Milestones

Indication	Milestone	Status	
Liver Cancer	Patients' enrollment to Phase II 78 patients study	Initiation: Q3-2014	
Rheumatoid Arthritis	Phase III planning	Q4-2014	
Psoriasis	Data from Phase II/III 300 patients study	Q1-2015	
Biomarker	Development of a commercial kit	2014	

(NYSE MKT:CANF) (TASE:CFBI)

۲



